Remarkably, around 84–89% of metastatic tumors harbor somatic mutations in BAP1. Hence, BAP1 alterations are strongly correlated with a higher metastatic risk and reduced survival rate [10,15,59,91,92]. Here, BAP1 is linked to metastatic neoplasm.